Targeting Chemoprevention of Colorectal Cancer to Those Who Are Likely to Respond
Tóm tắt
In the past four decades, chemoprevention of colorectal cancer (CRC) has been the subject of many epidemiologic and intervention trials of naturally occurring or pharmacologic agents. Recently, the positioning of cyclooxygenase 2 inhibitors as a viable option in this context was a major breakthrough; however, it was hampered by adverse cardiovascular events. This review questions whether chemopreventive measures for CRC are ready to be used in mass or individual applications, standing alone or in combination with other CRC-preventive measures. It also discusses steps that may be undertaken to explore this field further.
Tài liệu tham khảo
Vogelaar I, van Ballegooijen M, Schrag D, et al.: How much can current interventions reduce colorectal cancer mortality in the U.S.? Cancer 2006, 107:1624–1633.
Anderson JC, Messina CR, Dakhllahlah F, et al.: Body mass index, a marker for significant colorectal neoplasia in a screening population. J Clin Gastroenterol 2007, 41:285–290.
•• Das D, Arber N, Jankowski JA: Chemoprevention of colorectal cancer. Digestion 2007, 76:51–67. This is an excellent review of existing and future options for chemoprevention of CRC.
Dutch TIA Trial Study Group: A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991, 325:1261–1266.
Winawer SJ, Zauber AG, Fletcher RH, et al.: Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 2006, 2006:1872–1885.
Rockey DC, Barish M, Brill JV, et al.: Standards for gastroenterologists for performing and interpreting diagnostic computed tomographic colonography. Gastroenterology 2007, 133:1005–1024.
Kim DH, Pickhardt PJ, Taylor AJ, et al.: Colonography versus colonoscopy for the detection of advanced neoplasia. N Engl J Med 2007, 357:1403–1412.
Morikawa T, Kato J, Yamaji Y, et al.: A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005, 129:422–428.
Winawer SJ, Zauber AG, Ho MN, et al.: Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 1993, 329:1977–1981.
•• Arber N, Eagle CJ, Spicak J, et al.: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006, 355:885–895. This landmark study provides a model for testing future chemopreventive actions against CRC.
Solomon SD, McMurray JJ, Pfeffer MA, et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071–1080.
Shpitz B, Giladi N, Sagiv E, et al.: Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. Digestion 2006, 74:140–144.